This site is intended for U.S. health care professionals only.
18.3 month (95% CI: 15.1-NE) median PFS was observed with LENVIMA vs 3.6 months (95% CI:
2.2-3.7) with placebo (HR: 0.21 [95% CI: 0.16-0.28]; P<0.001; primary endpoint)1
CI=confidence interval; NE=not estimable; PFS=progression-free survival; HR=hazard ratio; AR=adverse reaction.
See efficacy data
Help manage ARs
Get downloadable resources
Not an actual patient